Artelo biosciences reports second quarter 2024 financial results and provides business update

Solana beach, calif., aug. 13, 2024 (globe newswire) -- artelo biosciences, inc. (nasdaq: artl), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today reported its financial and operating results for the three months ended june 30, 2024 and provided a business update.
ARTL Ratings Summary
ARTL Quant Ranking